Who is sponsoring NCT03741387?

NCT03741387 is sponsored by Guangzhou Blood Center.

What drugs are being tested in NCT03741387?

Interventions in NCT03741387: Gain-frame questionnaire, Loss-frame questionnaire.

What condition does NCT03741387 study?

NCT03741387 studies Rh Negative Blood Donor.

Is NCT03741387 still recruiting?

NCT03741387 is currently completed. Last updated 26 March 2019.

Last reviewed 2019-03-26 · How we verify

NCT03741387

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Message Framing on Blood Donation-Study 2

Completed NA Last updated 26 March 2019

What this trial tests

NA trial testing Gain-frame questionnaire in Rh Negative Blood Donor in 795 participants. Completed in 21 March 2019.

Timeline

15 March 2019

Primary endpoint
21 March 2019

21 March 2019

Quick facts

Lead sponsor	Guangzhou Blood Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	795
Start date	15 March 2019
Primary completion	21 March 2019
Estimated completion	21 March 2019
Sites	1 location across China

Drugs / interventions tested

Gain-frame questionnaire
Loss-frame questionnaire

Conditions studied

Rh Negative Blood Donor — all drugs for Rh Negative Blood Donor →

Sponsor

Guangzhou Blood Center — full company profile →

Who can join

Adults 18 to 60, any sex, with Rh Negative Blood Donor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rh negative blood group is a rare blood group in China, as it only accounts for 0.3-0.4 percent of the Han population. Therefore, low inventory is often found in blood collection and supply agencies in many regions in China. In order to assess the effects of the gain-versus-loss framing message on blood donation among Rh negative donors, we designed two kinds of self-administered, standardized and structured questionnaires. In addition of the basic socio-demographic characteristics, one questionnaire includes the questions which survey the attitude of saving patients lives, and the other was to survey the attitude of preventing patients from death. The questionnaires were randomly sent to Rh negative blood donors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Guangzhou Blood Center trials

Trials by the same sponsor.

NCT05213130 — Blood Donation and Subjective Well-being · NA · completed
NCT05319951 — Effect of Different Liquids Intake in Vasovagal Reaction After Whole Blood Donation · NA · completed
NCT04484896 — Message Framing on Recruiting Rh-D Negative Blood Donors · NA · unknown
NCT04431180 — Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial# · NA · unknown
NCT04410458 — Recruit Blood Donors Via SMS During Epidemic of COVID-19 （Repeat Trial） · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03741387 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Blood Center
Last refreshed: 26 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03741387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing